Anke Bio’s PEGylated human interferon α2b approved by the CFDA

May 13, 2014

The product can be used for the treatment of viral hepatitis, cancer and acute infectious diseases and will compete with Tonghua Dongbao’s PEGasys and Roche’s and Scheering-Plough’s products

China Bio news release, May 13, 2014

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny